DE3681787D1
(de)
*
|
1985-07-05 |
1991-11-07 |
Whitehead Biomedical Inst |
Expression von fremdem genetischem material in epithelzellen.
|
US5266480A
(en)
*
|
1986-04-18 |
1993-11-30 |
Advanced Tissue Sciences, Inc. |
Three-dimensional skin culture system
|
US5219740A
(en)
*
|
1987-02-13 |
1993-06-15 |
Fred Hutchinson Cancer Research Center |
Retroviral gene transfer into diploid fibroblasts for gene therapy
|
US6048729A
(en)
*
|
1987-05-01 |
2000-04-11 |
Transkaryotic Therapies, Inc. |
In vivo protein production and delivery system for gene therapy
|
US6544771B1
(en)
|
1987-12-11 |
2003-04-08 |
Cell Genesys, Inc. |
Retroviral gene therapy vectors and therapeutic methods based thereon
|
US6140111A
(en)
*
|
1987-12-11 |
2000-10-31 |
Whitehead Institute For Biomedical Research |
Retroviral gene therapy vectors and therapeutic methods based thereon
|
US6001350A
(en)
*
|
1987-12-11 |
1999-12-14 |
Somatix Therapy Corp |
Genetic modification of endothelial cells
|
WO1989007136A2
(en)
|
1988-02-05 |
1989-08-10 |
Whitehead Institute For Biomedical Research |
Modified hepatocytes and uses therefor
|
US5580776A
(en)
*
|
1988-02-05 |
1996-12-03 |
Howard Hughes Medical Institute |
Modified hepatocytes and uses therefor
|
EP0432216A1
(de)
*
|
1988-09-01 |
1991-06-19 |
Whitehead Institute For Biomedical Research |
Rekombinante retroviren mit amphotropen und ecotropen wirtsspektren
|
FR2649119A1
(fr)
*
|
1989-06-30 |
1991-01-04 |
Centre Nat Rech Scient |
Procede de pilotage de retrovirus en utilisant des complexes bifonctionnels
|
EP1001032A3
(de)
*
|
1989-08-18 |
2005-02-23 |
Chiron Corporation |
Rekombinante Retroviren um Vektorkonstruktionen an Zielzellen zu liefern
|
GB8919607D0
(en)
*
|
1989-08-30 |
1989-10-11 |
Wellcome Found |
Novel entities for cancer therapy
|
US6337209B1
(en)
|
1992-02-26 |
2002-01-08 |
Glaxo Wellcome Inc. |
Molecular constructs containing a carcinoembryonic antigen regulatory sequence
|
CA2092323A1
(en)
*
|
1990-10-01 |
1992-04-02 |
George Y. Wu |
Targeting viruses and cells for selective internalization by cells
|
WO1992007943A1
(en)
*
|
1990-10-31 |
1992-05-14 |
Somatix Therapy Corporation |
Retroviral vectors useful for gene therapy
|
CA2076848A1
(en)
*
|
1990-12-26 |
1992-06-27 |
Richard C. Mulligan |
Modified hepatocytes and uses therefor
|
WO1992019749A1
(en)
*
|
1991-05-03 |
1992-11-12 |
The Board Of Regents Acting For And On Behalf Of The University Of Michigan |
Targeted delivery of genes encoding cell surface receptors
|
US5904920A
(en)
*
|
1991-10-04 |
1999-05-18 |
Whitehead Institute For Biomedical Research |
Regulation of systemic immune responses utilizing cytokines and antigens
|
SE503225C2
(sv)
*
|
1991-10-30 |
1996-04-22 |
Leif Lindholm Konsult Ab |
Virus-antikroppskomplex för införing av virus i mammalieceller
|
US6692737B1
(en)
|
1991-11-05 |
2004-02-17 |
Transkaryotic Therapies, Inc. |
In vivo protein production and delivery system for gene therapy
|
US6054288A
(en)
*
|
1991-11-05 |
2000-04-25 |
Transkaryotic Therapies, Inc. |
In vivo protein production and delivery system for gene therapy
|
US6063630A
(en)
|
1991-11-05 |
2000-05-16 |
Transkaryotic Therapies, Inc. |
Targeted introduction of DNA into primary or secondary cells and their use for gene therapy
|
NZ245015A
(en)
*
|
1991-11-05 |
1995-12-21 |
Transkaryotic Therapies Inc |
Delivery of human growth hormone through the administration of transfected cell lines encoding human growth hormone, which are physically protected from host immune response; the transfected cells and their production
|
US6531124B1
(en)
|
1992-07-10 |
2003-03-11 |
Transkaryotic Therapies, Inc. |
In vivo production and delivery of insulinotropin for gene therapy
|
US6670178B1
(en)
|
1992-07-10 |
2003-12-30 |
Transkaryotic Therapies, Inc. |
In Vivo production and delivery of insulinotropin for gene therapy
|
WO1994015459A1
(en)
*
|
1993-01-05 |
1994-07-21 |
The General Hospital Corporation |
Method for isolation and transplantation of specialized hepatocytes
|
US6506604B2
(en)
*
|
1993-06-11 |
2003-01-14 |
Cell Genesys, Inc. |
Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells
|
US5591625A
(en)
*
|
1993-11-24 |
1997-01-07 |
Case Western Reserve University |
Transduced mesenchymal stem cells
|
US5728518A
(en)
*
|
1994-01-12 |
1998-03-17 |
The Immune Response Corporation |
Antiviral poly-and oligonucleotides
|
US5869248A
(en)
*
|
1994-03-07 |
1999-02-09 |
Yale University |
Targeted cleavage of RNA using ribonuclease P targeting and cleavage sequences
|
IL113052A0
(en)
|
1994-03-23 |
1995-06-29 |
Rhone Poulenc Rorer Sa |
Recombinant viruses, their preparation and their use in gene therapy
|
AU695618B2
(en)
*
|
1994-04-11 |
1998-08-20 |
Baylor College Of Medicine |
Compositions and methods for gene therapy to treat disease
|
US6150137A
(en)
|
1994-05-27 |
2000-11-21 |
Ariad Pharmaceuticals, Inc. |
Immunosuppressant target proteins
|
US6814962B1
(en)
*
|
1994-06-02 |
2004-11-09 |
Aventis Pharma S.A. |
Recombinant viruses and their use for treatment of atherosclerosis and other forms of coronary artery disease and method, reagent, and kit for evaluating susceptibility to same
|
WO1996011268A1
(en)
*
|
1994-10-06 |
1996-04-18 |
Warner-Lambert Company |
Method of using a scavenger receptor in the treatment of atherosclerosis
|
US5683873A
(en)
*
|
1995-01-13 |
1997-11-04 |
Innovir Laboratories, Inc. |
EGS-mediated inactivation of target RNA
|
US6057153A
(en)
*
|
1995-01-13 |
2000-05-02 |
Yale University |
Stabilized external guide sequences
|
US5652224A
(en)
*
|
1995-02-24 |
1997-07-29 |
The Trustees Of The University Of Pennsylvania |
Methods and compositions for gene therapy for the treatment of defects in lipoprotein metabolism
|
CA2229287A1
(en)
*
|
1995-08-14 |
1997-02-27 |
Cornell Research Foundation, Inc. |
Regulation of cellular functions by ectopic expression of non-endogenous cell signalling receptors
|
US6689757B1
(en)
|
1996-02-12 |
2004-02-10 |
M.L. Laboratories Plc |
Methods for vaccination and vaccines therefor
|
US5869243A
(en)
*
|
1996-03-05 |
1999-02-09 |
Rhode Island Hospital |
Immortalized hepatocytes
|
FR2746109B1
(fr)
|
1996-03-12 |
1998-04-17 |
Rhone Poulenc Rorer Sa |
Milieu pour la conservation de materiel biologique
|
US5877162A
(en)
*
|
1996-03-14 |
1999-03-02 |
Innovir Laboratories, Inc. |
Short external guide sequences
|
US5888982A
(en)
*
|
1996-04-01 |
1999-03-30 |
President And Fellows Of Harvard College |
Regulation of vascular smooth muscle cell heme oxygenase-1
|
US5945100A
(en)
|
1996-07-31 |
1999-08-31 |
Fbp Corporation |
Tumor delivery vehicles
|
US7332338B2
(en)
|
1996-10-04 |
2008-02-19 |
Lexicon Pharmaceuticals, Inc. |
Vectors for making genomic modifications
|
US20040072243A1
(en)
*
|
1996-10-11 |
2004-04-15 |
Lexicon Genetics Incorporated |
Indexed library of cells containing genomic modifications and methods of making and utilizing the same
|
US6096303A
(en)
*
|
1997-07-31 |
2000-08-01 |
Medical College Of Georgia Research Institute, Inc. |
Method to enhance treatment of cystic tumors
|
US6441158B1
(en)
|
1997-12-31 |
2002-08-27 |
Medical College Of Georgia Research Institute, Inc. |
Oligomers that bind to ku protein
|
CA2305787A1
(en)
|
2000-05-09 |
2001-11-09 |
The University Of British Columbia |
Cxcr4 antagonist treatment of hematopoietic cells
|
CA2245224A1
(en)
|
1998-08-14 |
2000-02-14 |
Jiang-Hong Giong |
Chemokine receptor antagonists and chemotherapeutics
|
WO1999047158A2
(en)
|
1998-03-13 |
1999-09-23 |
The University Of British Columbia |
Therapeutic chemokine receptor antagonists
|
US6436707B1
(en)
|
1998-03-27 |
2002-08-20 |
Lexicon Genetics Incorporated |
Vectors for gene mutagenesis and gene discovery
|
US6808921B1
(en)
|
1998-03-27 |
2004-10-26 |
Lexicon Genetics Incorporated |
Vectors for gene mutagenesis and gene discovery
|
US6080576A
(en)
*
|
1998-03-27 |
2000-06-27 |
Lexicon Genetics Incorporated |
Vectors for gene trapping and gene activation
|
DE19956568A1
(de)
|
1999-01-30 |
2000-08-17 |
Roland Kreutzer |
Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
|
IL139321A0
(en)
|
1999-03-03 |
2001-11-25 |
Biogen Inc |
Methods and compositions for modulating lipid metabolism
|
JP2002537835A
(ja)
|
1999-03-12 |
2002-11-12 |
ジーピーシー バイオテク インコーポレイテッド |
合成遺伝子エレメントを同定する方法及び試薬
|
US7396905B1
(en)
|
1999-05-21 |
2008-07-08 |
Mckeon Frank |
Calcipressins: endogenous inhibitors of calcineurin, uses and reagents related thereto
|
US6436302B1
(en)
|
1999-08-23 |
2002-08-20 |
Applied Materials, Inc. |
Post CU CMP polishing for reduced defects
|
DE10100586C1
(de)
|
2001-01-09 |
2002-04-11 |
Ribopharma Ag |
Verfahren zur Hemmung der Expression eines Ziegens
|
US8168178B2
(en)
|
1999-11-30 |
2012-05-01 |
Curis, Inc. |
Methods and compositions for regulating lymphocyte activity
|
US6951839B1
(en)
|
1999-11-30 |
2005-10-04 |
Curis, Inc. |
Methods and compositions for regulating lymphocyte activity
|
EP1254169B1
(de)
|
1999-12-30 |
2007-05-09 |
President And Fellows of Harvard College |
Verfahren zur modulierung der aktivität von th2-zellen durch modulierung der aktivität von xbp-1
|
US7368425B2
(en)
|
2006-03-24 |
2008-05-06 |
Chemokine Therapeutics Corp. |
Cyclic peptides for modulating growth of neo-vessels and their use in therapeutic angiogenesis
|
US7378098B2
(en)
|
2000-04-12 |
2008-05-27 |
The University Of British Columbia |
CXC chemokine receptor 4 agonist peptides
|
US20050059584A1
(en)
|
2002-08-16 |
2005-03-17 |
Ahmed Merzouk |
Novel chemokine mimetics synthesis and their use
|
WO2002014867A2
(en)
|
2000-08-11 |
2002-02-21 |
Agilix Corporation |
Ultra-sensitive detection systems
|
EP2336166A1
(de)
|
2000-10-12 |
2011-06-22 |
University Of Rochester |
Zusammensetzungen die die Proliferation von Krebszellen hemmen
|
US7423142B2
(en)
|
2001-01-09 |
2008-09-09 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of anti-apoptotic genes
|
US7767802B2
(en)
|
2001-01-09 |
2010-08-03 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of anti-apoptotic genes
|
US20030170642A1
(en)
*
|
2001-03-12 |
2003-09-11 |
Irm, Llc |
Identification of cellular targets for biologically active molecules
|
WO2002072789A2
(en)
*
|
2001-03-12 |
2002-09-19 |
Irm, Llc. |
Genomics-driven high speed cellular assays, development thereof, and collections of cellular reporters
|
WO2002094871A1
(en)
|
2001-05-24 |
2002-11-28 |
Human Dna Technology Inc |
Novel keratinocyte growth factor-2 analogue in hair follicle
|
CA2921821A1
(en)
|
2001-07-12 |
2003-01-23 |
University Of Massachusetts |
In vivo production of small interfering rnas that mediate gene silencing
|
EP1900815B1
(de)
|
2001-07-12 |
2016-09-07 |
University of Massachusetts |
In-vivo-Herstellung kleiner interferierender und Genverstummung vermittelnder RNAs
|
JP2005500881A
(ja)
|
2001-08-09 |
2005-01-13 |
アイボクラー ヴィヴェイデント インコーポレイテッド |
組織インプラント、ならびにその作製方法および使用方法
|
US7176278B2
(en)
|
2001-08-30 |
2007-02-13 |
Biorexis Technology, Inc. |
Modified transferrin fusion proteins
|
IL161110A0
(en)
|
2001-09-28 |
2004-08-31 |
Esperion Therapeutics Inc |
Prevention and treatment of restenosis by local admistration of drug
|
US7534774B2
(en)
|
2001-10-03 |
2009-05-19 |
Tissue Repair Company |
Traversal of nucleic acid molecules through a fluid space and expression in repair cells
|
US7745418B2
(en)
|
2001-10-12 |
2010-06-29 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting viral replication
|
US7255874B1
(en)
|
2001-12-21 |
2007-08-14 |
Closure Medical Corporation |
Biocompatible polymers and adhesives: compositions, methods of making and uses related thereto
|
US20030124652A1
(en)
*
|
2001-12-21 |
2003-07-03 |
Novazyme Pharmaceuticals, Inc. |
Methods of producing high mannose glycoproteins in complex carbohydrate deficient cells
|
IL152904A0
(en)
|
2002-01-24 |
2003-06-24 |
Gamida Cell Ltd |
Utilization of retinoid and vitamin d receptor antagonists for expansion of renewable stem cell populations
|
AU2003265228A1
(en)
*
|
2002-03-12 |
2003-12-22 |
Surface Logix, Inc. |
Assay device that analyzes the absorption, metabolism, permeability and/or toxicity of a candidate compound
|
EP1490085A2
(de)
|
2002-03-25 |
2004-12-29 |
Uab Research Foundation |
Rezeptor-homolog, reagenzien und derer verwendungen
|
CA2421269A1
(en)
|
2002-08-09 |
2004-02-09 |
President And Fellows Of Harvard College |
Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
|
CA2499770A1
(en)
|
2002-09-20 |
2004-04-01 |
Yale University |
Riboswitches, methods for their use, and compositions for use with riboswitches.
|
US8658377B2
(en)
|
2002-11-15 |
2014-02-25 |
Morehouse School Of Medicine |
Detecting cancer with anti-CCL25 and anti-CCR9 antibodies
|
US8512701B2
(en)
|
2002-11-15 |
2013-08-20 |
Morehouse School Of Medicine |
Anti-CXCL13 and anti-CXCR5 antibodies for the prevention and treatment of cancer and cancer cell migration
|
US9233120B2
(en)
|
2002-11-15 |
2016-01-12 |
Jyant Technologies |
Anti-CCL25 and anti-CCR9 antibodies for the prevention and treatment of cancer and cancer cell migration
|
EP2292259A3
(de)
|
2002-11-15 |
2011-03-23 |
MUSC Foundation For Research Development |
Komplement-Modulatoren für Komplement-Rezeptor 2
|
DE60334246D1
(de)
|
2002-11-21 |
2010-10-28 |
Celltech R & D Inc |
Modulieren von immunantworten
|
CA2513251C
(en)
|
2003-01-14 |
2013-03-19 |
Dana-Farber Cancer Institute |
Cancer therapy sensitizer
|
EP1624936B1
(de)
|
2003-05-16 |
2009-10-28 |
Universite Laval |
Cns chlorid-modulierung und verwendung derselben
|
EP3502252B1
(de)
|
2003-06-02 |
2023-04-05 |
University of Massachusetts |
Verfahren und zusammensetzungen zur kontrolle der wirksamkeit von rna-silencing
|
ES2864206T3
(es)
|
2003-06-02 |
2021-10-13 |
Univ Massachusetts |
Métodos y composiciones para mejorar la eficacia y la especificidad del ARNi
|
SI2270162T1
(sl)
|
2003-06-12 |
2019-03-29 |
Alnylam Pharmaceuticals Inc. |
Konzervirana HBV in HCV zaporedja uporabna za utišanje genov
|
ITRM20030395A1
(it)
*
|
2003-08-12 |
2005-02-13 |
Istituto Naz Per Le Malattie Infettive Lazz |
Terreno di coltura per il mantenimento, la proliferazione e il differenziamento di cellule di mammifero.
|
CA2540244A1
(en)
*
|
2003-09-30 |
2005-04-14 |
Lexicon Genetics Incorporated |
Methods and compositions for defining gene function
|
EP1677735B1
(de)
|
2003-10-17 |
2014-07-23 |
Joslin Diabetes Center, Inc. |
Verfahren und zusammensetzungen zur modulierung der adipozyten-funktion
|
EP1918000A2
(de)
|
2003-11-05 |
2008-05-07 |
Schering Corporation |
Verbindungen aus lipidverändernden Wirkstoffen und substituierten Azetidinonen und Behandlungen für Gefäßzustände
|
WO2005069969A2
(en)
|
2004-01-21 |
2005-08-04 |
University Of Utah Research Foundation |
Mutant sodium channel nav1.7 and methods related thereto
|
AU2005222902B2
(en)
|
2004-03-12 |
2010-06-10 |
Alnylam Pharmaceuticals, Inc. |
iRNA agents targeting VEGF
|
US20050223202A1
(en)
*
|
2004-03-31 |
2005-10-06 |
Intel Corporation |
Branch prediction in a pipelined processor
|
US8926958B2
(en)
|
2004-04-06 |
2015-01-06 |
Cedars-Sinai Medical Center |
Prevention and treatment of vascular disease with recombinant adeno-associated virus vectors encoding apolipoprotein A-I and apolipoprotein A-I milano
|
NZ550772A
(en)
|
2004-05-21 |
2009-10-30 |
Uab Research Foundation |
Variable lymphocyte receptors, related polypeptides and nucleic acids, and uses thereof
|
US7846438B2
(en)
|
2004-08-03 |
2010-12-07 |
Biogen Idec Ma Inc. |
Methods of promoting neurite outgrowth with soluble TAJ polypeptides
|
EP2374469A3
(de)
|
2004-12-21 |
2012-01-25 |
MUSC Foundation For Research Development |
Zusammensetzungen und Verfahren zur Förderung der Wundheilung und Geweberegeneration
|
CA2592099A1
(en)
|
2004-12-22 |
2006-06-29 |
Nucleonics, Inc. |
Conserved hbv and hcv sequences useful for gene silencing
|
US20090124993A1
(en)
|
2005-02-17 |
2009-05-14 |
Burkly Linda C |
Treating neurological disorders
|
RU2596491C2
(ru)
|
2005-06-08 |
2016-09-10 |
Дана-Фарбер Кэнсер Инститьют |
Способы и композиции для лечения персистирующих инфекций
|
EP2189522A1
(de)
|
2005-10-14 |
2010-05-26 |
MUSC Foundation For Research Development |
PAX2 als Ziel zur Induktion einer Immunität gegen DEFB1-vermittelte Tumore und bei der Krebstherapie
|
US8080534B2
(en)
|
2005-10-14 |
2011-12-20 |
Phigenix, Inc |
Targeting PAX2 for the treatment of breast cancer
|
WO2007056326A2
(en)
|
2005-11-04 |
2007-05-18 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of nav1.8 gene
|
CA2626690A1
(en)
|
2005-11-09 |
2007-05-18 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of factor v leiden mutant gene
|
CN101360826B
(zh)
|
2005-11-18 |
2014-04-30 |
格兰马克药品股份有限公司 |
抗α2整联蛋白抗体及它们的用途
|
US8846393B2
(en)
|
2005-11-29 |
2014-09-30 |
Gamida-Cell Ltd. |
Methods of improving stem cell homing and engraftment
|
DE602006020071D1
(de)
*
|
2005-12-21 |
2011-03-24 |
Univ Catholique Louvain |
Isolierte leberstammzellen
|
JP2009523129A
(ja)
|
2006-01-05 |
2009-06-18 |
ユニバーシティ オブ ユタ リサーチ ファウンデーション |
神経系を標的する薬理学的物質の性質を改善することに関連する方法および組成物
|
AU2007223427A1
(en)
|
2006-03-01 |
2007-09-13 |
University Of Utah Research Foundation |
Methods and compositions related to cyclic peptide synthesis
|
US8470965B2
(en)
|
2006-03-01 |
2013-06-25 |
University Of Utah Research Foundation |
Methods and compositions related to cyclic peptide synthesis
|
NZ571568A
(en)
|
2006-03-31 |
2010-11-26 |
Alnylam Pharmaceuticals Inc |
Double-stranded RNA molecule compositions and methods for inhibiting expression of Eg5 gene
|
WO2007127919A2
(en)
|
2006-04-28 |
2007-11-08 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of a gene from the jc virus
|
CN103614375A
(zh)
|
2006-05-11 |
2014-03-05 |
阿尔尼拉姆医药品有限公司 |
抑制pcsk9基因表达的组合物和方法
|
CA2652770A1
(en)
|
2006-05-19 |
2007-11-29 |
Alnylam Pharmaceuticals, Inc. |
Rnai modulation of aha and therapeutic uses thereof
|
WO2007137220A2
(en)
|
2006-05-22 |
2007-11-29 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of ikk-b gene
|
US10119979B2
(en)
|
2006-05-25 |
2018-11-06 |
Biogen Ma Inc. |
Methods of treating stroke and traumatic brain injury using humanized AQC2 anti-VLA-1 antibodies
|
US8598333B2
(en)
|
2006-05-26 |
2013-12-03 |
Alnylam Pharmaceuticals, Inc. |
SiRNA silencing of genes expressed in cancer
|
JP5926475B2
(ja)
|
2006-09-21 |
2016-05-25 |
ユニバーシティー オブ ロチェスター |
筋緊張性ジストロフィーのためのタンパク質置換治療に関する組成物および方法
|
CN101663323A
(zh)
|
2006-12-27 |
2010-03-03 |
埃默里大学 |
用于治疗传染病和肿瘤的组合物和方法
|
US9896511B2
(en)
|
2007-01-10 |
2018-02-20 |
The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services |
Antibodies that bind to TL1A and methods of treating inflammatory or autoimmune disease comprising administering such antibodies
|
US20120030779A1
(en)
|
2007-01-18 |
2012-02-02 |
University Of Utah Research Foundtion |
Compositions and methods for detecting, treating, or preventing reductive stress
|
EP2629094A1
(de)
|
2007-01-24 |
2013-08-21 |
Carnegie Mellon University |
Optische Biosensoren
|
WO2008121437A2
(en)
|
2007-02-08 |
2008-10-09 |
The Burnham Institute For Medical Research |
Trophinin-binding peptides and uses thereof
|
JP2010521977A
(ja)
|
2007-03-22 |
2010-07-01 |
イェール ユニバーシティー |
オルタナティブスプライシングを調節するリボスイッチに関する方法および組成物
|
PE20090064A1
(es)
|
2007-03-26 |
2009-03-02 |
Novartis Ag |
Acido ribonucleico de doble cadena para inhibir la expresion del gen e6ap humano y composicion farmaceutica que lo comprende
|
CA2687024A1
(en)
|
2007-05-09 |
2009-02-19 |
Burnham Institute For Medical Research |
Targeting host proteinases as a therapeutic strategy against viral and bacterial pathogens
|
JP2010528617A
(ja)
|
2007-05-29 |
2010-08-26 |
イェール ユニバーシティー |
リボスイッチならびにリボスイッチを使用するためのおよびリボスイッチと共てに使用するための方法および組成物
|
US20100184823A1
(en)
|
2007-07-05 |
2010-07-22 |
Mark Aron Labow |
dsRNA For Treating Viral Infection
|
EP2268664B1
(de)
|
2007-12-03 |
2017-05-24 |
The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services |
Doc1-zusammensetzungen und verfahren zur behandlung von krebs
|
EP2245159A2
(de)
|
2007-12-10 |
2010-11-03 |
Alnylam Pharmaceuticals Inc. |
Zusammensetzungen und verfahren zur hemmung der expression des faktor-vii-gens
|
CA2716793A1
(en)
|
2008-03-05 |
2009-09-11 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of eg5 and vegf genes
|
EP2283119B1
(de)
|
2008-05-06 |
2015-01-07 |
Joslin Diabetes Center, Inc. |
Verfahren und zusammensetzungen zur einleitung von brauner adipogenese
|
US8946291B2
(en)
|
2008-08-15 |
2015-02-03 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Compositions and methods for treating pigmentary conditions and melanoma
|
EP3208337A1
(de)
|
2008-09-02 |
2017-08-23 |
Alnylam Pharmaceuticals, Inc. |
Zusammensetzungen zur kombinationshemmung der expression eines mutanten egfr und il-6
|
JP5529142B2
(ja)
|
2008-09-25 |
2014-06-25 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
血清アミロイドa遺伝子の発現を阻害するための脂質製剤組成物および方法
|
US8168775B2
(en)
|
2008-10-20 |
2012-05-01 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of transthyretin
|
EP2343361A4
(de)
*
|
2008-10-24 |
2013-10-09 |
Kuraray Co |
Zellkulturkit, prüfverfahren und herstellungsverfahren für das zellkulturkit
|
EP2894165B1
(de)
|
2008-11-10 |
2023-01-04 |
Alexion Pharmaceuticals, Inc. |
Verfahren und Zusammensetzungen zur Behandlung von komplementassoziierten Störungen
|
WO2010065617A1
(en)
|
2008-12-02 |
2010-06-10 |
University Of Utah Research Foundation |
Pde1 as a target therapeutic in heart disease
|
AU2009324534B2
(en)
|
2008-12-10 |
2015-07-30 |
Alnylam Pharmaceuticals, Inc. |
GNAQ targeted dsRNA compositions and methods for inhibiting expression
|
MX2011008936A
(es)
|
2009-02-24 |
2011-09-21 |
Alexion Pharma Inc |
Anticuerpos que contienen peptidos terapeuticos mimeticos de tpo/epo.
|
WO2010099341A1
(en)
|
2009-02-26 |
2010-09-02 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of mig-12 gene
|
US20100267806A1
(en)
|
2009-03-12 |
2010-10-21 |
David Bumcrot |
LIPID FORMULATED COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF Eg5 AND VEGF GENES
|
CA2755870C
(en)
|
2009-03-20 |
2019-04-09 |
Angioblast Systems, Inc. |
Production of reprogrammed pluripotent cells
|
US20120107331A1
(en)
|
2009-05-15 |
2012-05-03 |
Yale University |
Gemm riboswitches, structure-based compound design with gemm riboswitches, and methods and compositions for use of and with gemm riboswitches
|
WO2011005496A2
(en)
|
2009-06-22 |
2011-01-13 |
Massachusetts Eye & Ear Infirmary |
Islet1 (isl1) and hearing loss
|
WO2011050210A1
(en)
|
2009-10-21 |
2011-04-28 |
Agios Pharmaceuticals, Inc. |
Methods and compositions for cell-proliferation-related disorders
|
SG182365A1
(en)
|
2010-01-12 |
2012-08-30 |
Univ Yale |
Structured rna motifs and compounds and methods for their use
|
EP2524054A2
(de)
|
2010-01-14 |
2012-11-21 |
Haplomics, Inc. |
Vorhersage und reduktion der alloimmunogenität von proteintherapeutika
|
WO2011088163A1
(en)
|
2010-01-14 |
2011-07-21 |
President And Fellows Of Harvard College |
Methods for modulating skeletal remodeling and patterning by modulating shn2 activity, shn3 activity, or shn2 and shn3 activity in combination
|
ES2893199T3
(es)
|
2010-03-29 |
2022-02-08 |
Alnylam Pharmaceuticals Inc |
Terapia de ARNbc para amiloidosis ocular relacionada con transtiretina (TTR)
|
NZ629829A
(en)
|
2010-04-30 |
2015-11-27 |
Alexion Pharma Inc |
Anti-c5a antibodies and methods for using the antibodies
|
US20130143955A1
(en)
|
2010-08-09 |
2013-06-06 |
Yale University |
Cyclic di-GMP-II Riboswitches, Motifs, and Compounds, and Methods for Their Use
|
US10004826B2
(en)
|
2010-10-06 |
2018-06-26 |
Massachusetts Institute Of Technology |
Implantable human liver tissue constructs and uses thereof
|
WO2012051301A1
(en)
|
2010-10-12 |
2012-04-19 |
President And Fellows Of Harvard College |
Methods for identifying modulators of triglyceride metabolism, for modulating triglyceride metabolism and for identifying subjects at risk for abnormal triglyceride metabolism
|
US8815942B2
(en)
|
2010-10-20 |
2014-08-26 |
The Royal Institution For The Advancement Of Learning/Mcgill University |
Combination therapy and uses thereof for treatment and prevention of parasitic infection and disease
|
JP2014505239A
(ja)
|
2010-12-14 |
2014-02-27 |
モアハウス スクール オブ メディスン |
癌の治療または検出のための抗cxcl13および抗cxcr5抗体の使用
|
AU2011343822B2
(en)
|
2010-12-15 |
2017-06-29 |
Neuroadjuvants, Inc. |
Neuropeptide analogs, compositions, and methods for treating pain
|
AU2011352228B2
(en)
|
2010-12-27 |
2015-12-03 |
Brown University |
Therapeutic and diagnostic methods involving biglycan and utrophin
|
US9956236B2
(en)
|
2011-02-07 |
2018-05-01 |
Cornell University |
Methods for increasing immune responses using agents that directly bind to and activate IRE-1
|
KR20140104344A
(ko)
|
2011-05-20 |
2014-08-28 |
더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 시크리터리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비시스 |
T 세포 매개성 질병의 병증을 개선하기 위한 tl1a-dr3의 상호작용의 차단 및 그것의 항체
|
US20130156803A1
(en)
|
2011-06-04 |
2013-06-20 |
Rochester General Hospital Research Institute |
Compositions and methods related to p6
|
KR102540778B1
(ko)
|
2011-06-21 |
2023-06-07 |
알닐람 파마슈티칼스 인코포레이티드 |
아포리포단백질 c-iii(apoc3) 유전자의 발현 억제를 위한 조성물 및 방법
|
US9068184B2
(en)
|
2011-06-21 |
2015-06-30 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibition of expression of protein C (PROC) genes
|
BR112014020119A2
(pt)
|
2012-02-13 |
2020-10-27 |
Gamida-Cell Ltd |
cultura de células-tronco mesenquimais
|
US9567569B2
(en)
|
2012-07-23 |
2017-02-14 |
Gamida Cell Ltd. |
Methods of culturing and expanding mesenchymal stem cells
|
US9175266B2
(en)
|
2012-07-23 |
2015-11-03 |
Gamida Cell Ltd. |
Enhancement of natural killer (NK) cell proliferation and activity
|
WO2014113540A1
(en)
|
2013-01-16 |
2014-07-24 |
Iowa State University Research Foundation, Inc. |
A deep intronic target for splicing correction on spinal muscular atrophy gene
|
EP2851086A1
(de)
|
2013-09-20 |
2015-03-25 |
Sanofi |
Serpine: Verfahren zur therapeutischen ß-Zellen-Regeneration und Funktion
|
US20160002316A1
(en)
|
2013-02-22 |
2016-01-07 |
Joslin Diabetes Center |
Serpins: methods of therapeutic beta-cell regeneration and function
|
EP2769732A1
(de)
|
2013-02-22 |
2014-08-27 |
Sanofi |
Serpine: Verfahren zur therapeutischen Beta-Zellen-Regeneration und Funktion
|
WO2014160418A2
(en)
|
2013-03-13 |
2014-10-02 |
GeneWeave Biosciences, Inc. |
Non-replicative transduction particles and transduction particle-based reporter systems
|
DK3016665T3
(da)
|
2013-07-05 |
2019-11-25 |
Univ Catholique Louvain |
Konditioneret medium fra humane voksne leverstamceller og dets anvendelse i behandlingen af leverlidelser
|
DK3049521T3
(en)
|
2013-09-25 |
2019-04-23 |
Univ Cornell |
Compounds for inducing antitumor immunity and methods thereof
|
WO2015123561A2
(en)
|
2014-02-14 |
2015-08-20 |
University Of Utah Research Foundation |
Methods and compositions for inhibiting retinopathy of prematurity
|
NZ711451A
(en)
|
2014-03-07 |
2016-05-27 |
Alexion Pharma Inc |
Anti-c5 antibodies having improved pharmacokinetics
|
US10494417B2
(en)
|
2014-03-25 |
2019-12-03 |
University Of Utah Research Foundation |
Peptide inhibitors of BCR-ABL oligomerization
|
CA2991750C
(en)
|
2014-07-24 |
2023-02-14 |
Massachusetts Eye & Ear Infirmary |
Rpgr gene therapy for retinitis pigmentosa
|
US10632151B2
(en)
|
2015-01-22 |
2020-04-28 |
University Of Massachusetts |
Cancer immunotherapy
|
EP3250588A1
(de)
|
2015-01-29 |
2017-12-06 |
Board of Trustees of Michigan State University |
Kryptische polypeptide und verwendungen davon
|
PL3265568T3
(pl)
|
2015-03-06 |
2020-11-30 |
Massachusetts Eye & Ear Infirmary |
Terapie augmentacji genów w przypadku wrodzonego zwyrodnienia siatkówki spowodowanego mutacjami genu prpf31
|
EP3735982A1
(de)
|
2015-03-10 |
2020-11-11 |
The University of Massachusetts |
Abzielung auf gdf6 und bmp-signalisierung für antimelanomtherapie
|
US10723794B2
(en)
|
2015-03-18 |
2020-07-28 |
University Of South Carolina |
Anti-CcL8 antibodies and uses thereof
|
WO2016183183A1
(en)
|
2015-05-11 |
2016-11-17 |
The Johns Hopkins University |
Autoimmune antibodies for use in inhibiting cancer cell growth
|
WO2016183585A1
(en)
|
2015-05-14 |
2016-11-17 |
Joslin Diabetes Center, Inc. |
Retinol-binding protein 3 (rbp3) as a protective factor in non-diabetic retinal degeneration
|
US11338065B2
(en)
|
2015-10-08 |
2022-05-24 |
Massachusetts Institute Of Technology |
In situ expansion of engineered devices for regeneration
|
WO2017066796A2
(en)
|
2015-10-16 |
2017-04-20 |
The Children's Medical Center Corporation |
Modulators of telomere disease
|
WO2017066712A2
(en)
|
2015-10-16 |
2017-04-20 |
The Children's Medical Center Corporation |
Modulators of telomere disease
|
CA3005878A1
(en)
|
2015-11-19 |
2017-05-26 |
The Brigham And Women's Hospital, Inc. |
Lymphocyte antigen cd5-like (cd5l)-interleukin 12b (p40) heterodimers in immunity
|
EP4310503A3
(de)
|
2015-12-30 |
2024-03-20 |
Momenta Pharmaceuticals, Inc. |
Verfahren im zusammenhang mit biologika
|
US11459568B2
(en)
|
2016-10-31 |
2022-10-04 |
University Of Massachusetts |
Targeting microRNA-101-3p in cancer therapy
|
EP3609577A4
(de)
|
2017-04-14 |
2021-03-24 |
University of Massachusetts |
Braune fettselektive adipokine
|
CA3066779A1
(en)
|
2017-06-28 |
2019-01-03 |
Regeneron Pharmaceuticals, Inc. |
Anti-human papillomavirus (hpv) antigen-binding proteins and methods of use thereof
|
US11365241B2
(en)
|
2017-07-27 |
2022-06-21 |
Alexion Pharmaceuticals, Inc. |
High concentration anti-C5 antibody formulations
|
CA3079409A1
(en)
|
2017-10-18 |
2019-04-25 |
Washington University |
Dominant negative sarm1 molecules as a therapeutic strategy for neurodegenerative diseases or disorders
|
US11008602B2
(en)
|
2017-12-20 |
2021-05-18 |
Roche Molecular Systems, Inc. |
Non-replicative transduction particles and transduction particle-based reporter systems
|
AU2019276372A1
(en)
|
2018-06-01 |
2020-12-24 |
Evotec International Gmbh |
Combination therapy for treating hepatitis B virus infection
|
DK3823665T3
(da)
|
2018-07-19 |
2024-03-04 |
Regeneron Pharma |
Kimæriske antigenreceptorer med BCMA-specificitet og anvendelser deraf
|
MA53981A
(fr)
|
2018-10-23 |
2021-09-01 |
Regeneron Pharma |
Récepteurs de lymphocytes t de ny-eso-1 et leurs procédés d'utilisation
|
WO2020120649A1
(en)
|
2018-12-13 |
2020-06-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Artificial antigen presenting cells that constitutively express an antigen along with a hla-class ii molecule
|
WO2020136154A1
(en)
|
2018-12-27 |
2020-07-02 |
F. Hoffmann-La Roche Ag |
Non-replicative transduction particles and transduction particle-based reporter systems for detection of acinetobacter baumannii
|
US11572595B2
(en)
|
2018-12-31 |
2023-02-07 |
Roche Molecular Systems, Inc. |
Non-replicative transduction particles with one or more non-native tail fibers and transduction particle-based reporter systems
|
IT201900007060A1
(it)
|
2019-05-21 |
2020-11-21 |
St Superiore Di Sanita |
Cellule tumorali ingegnerizzate e loro usi
|
IT201900012540A1
(it)
|
2019-07-22 |
2021-01-22 |
Humanitas Mirasole Spa |
Inibitori di CHI3L1 e loro usi
|
US20220281994A1
(en)
|
2019-07-24 |
2022-09-08 |
Regeneron Pharmaceuticals, Inc. |
Chimeric Antigen Receptors with MAGE-A4 Specificity and Uses Thereof
|
WO2021067526A1
(en)
|
2019-10-02 |
2021-04-08 |
Alexion Pharmaceuticals, Inc. |
Complement inhibitors for treating drug-induced complement-mediated response
|
JP2023505169A
(ja)
|
2019-12-03 |
2023-02-08 |
エヴォテック・インターナショナル・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
B型肝炎感染の治療における使用のためのインターフェロン会合抗原結合タンパク質
|
US20230242655A1
(en)
|
2019-12-03 |
2023-08-03 |
Evotec International Gmbh |
Interferon-associated antigen binding proteins and uses thereof
|
EP4085156B1
(de)
|
2019-12-31 |
2023-10-25 |
F. Hoffmann-La Roche AG |
Quantitatives pcr-screening von induzierbaren prophagen aus bakterienisolaten
|
WO2021150300A1
(en)
|
2020-01-22 |
2021-07-29 |
Massachusetts Institute Of Technology |
Inducible tissue constructs and uses thereof
|
CA3165827A1
(en)
|
2020-01-24 |
2021-07-29 |
Natalie BOWERMAN |
Preferentially expressed antigen in melanoma (prame) t cell receptors and methods of use thereof
|
WO2021217024A1
(en)
|
2020-04-24 |
2021-10-28 |
Millennium Pharmaceuticals, Inc. |
Anti-cd19 antibodies and uses thereof
|
US11826386B2
(en)
|
2020-05-05 |
2023-11-28 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for treating cancer
|
WO2022015902A1
(en)
|
2020-07-14 |
2022-01-20 |
Massachusetts Institute Of Technology |
Synthetic heparin mimetics and uses thereof
|
CN116615443A
(zh)
|
2020-09-14 |
2023-08-18 |
Vor生物制药股份有限公司 |
针对cd33的单结构域抗体
|
TW202241946A
(zh)
|
2020-12-18 |
2022-11-01 |
美商健生生物科技公司 |
針對整合素α11β1之抗體
|
JP2024502295A
(ja)
|
2020-12-24 |
2024-01-18 |
ノボキュア ゲーエムベーハー |
遺伝子治療において交流電場を使用するための方法及び組成物
|
CN117425673A
(zh)
|
2021-04-09 |
2024-01-19 |
武田药品工业株式会社 |
靶向补体因子d的抗体和其用途
|
EP4330283A1
(de)
|
2021-04-26 |
2024-03-06 |
Millennium Pharmaceuticals, Inc. |
Anti-adgre2-antikörper und verwendungen davon
|
KR20240004286A
(ko)
|
2021-04-26 |
2024-01-11 |
밀레니엄 파머슈티컬스 인코퍼레이티드 |
항 Clec12A 항체 및 이의 용도
|
AU2022271212A1
(en)
|
2021-05-04 |
2023-11-30 |
Regeneron Pharmaceuticals, Inc. |
Chimeric antigen receptors with mage-a4 specificity and uses thereof
|
EP4351732A1
(de)
|
2021-06-09 |
2024-04-17 |
Evotec International GmbH |
Interferon-assoziierte antigenbindende proteine zur verwendung zur behandlung oder prävention von coronavirus-infektionen
|
AU2022372894A1
(en)
|
2021-10-20 |
2024-04-18 |
Takeda Pharmaceutical Company Limited |
Compositions targeting bcma and methods of use thereof
|
WO2023201238A1
(en)
|
2022-04-11 |
2023-10-19 |
Vor Biopharma Inc. |
Binding agents and methods of use thereof
|
WO2023240109A1
(en)
|
2022-06-07 |
2023-12-14 |
Regeneron Pharmaceuticals, Inc. |
Multispecific molecules for modulating t-cell activity, and uses thereof
|